Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $41.00 | Buy | H.C. Wainwright |
| 3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP |
| 1/27/2025 | Overweight | Cantor Fitzgerald | |
| 12/13/2024 | $34.00 | Outperform | RBC Capital Mkts |
| 11/8/2024 | $33.00 | Buy | Guggenheim |
| 8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
| 12/3/2021 | $6.00 | Buy | H.C. Wainwright |
| 9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
SCHEDULE 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SCHEDULE 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the first participants have been dosed in its Phase 3 trial to evaluate the safety and efficacy of CD388, a non-vaccine preventative of seasonal influenza, in populations at high-risk for complications of influenza. Based on feedback from
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced updates to its planned Phase 3 registrational trial of CD388
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: September 9, 2025Time: 7:00 AM ETFormat: Fireside Chat Cidara will also participate in one-on-one investor meetings during the conferences. About Cidara Therapeuti
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
H.C. Wainwright resumed coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $41.00
Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00
Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, August 7, 2025Time:5:00 PM Eastern TimeUnited States:1-844-825-9789International:1-412-317-5180Conference
The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was well-tolerated with no safety signals observed End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA) Cidara will host a conference call at 8:30 am ET on Monday, June 23rd, 2025 SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)